WuXi Biologics announces structural completion and key equipment arrival at Chengdu microbial manufacturing site

HanchorBio chooses Bloomberg to enhance strategic intelligence across drug development and global biopharma

Ascletis completes enrolment for US Phase II study of ASC30 in diabetes

Novartis receives positive CHMP opinion for Itvisma in spinal muscular atrophy

Servier completes Day One Biopharmaceuticals acquisition

Orion Pharma launches Phase 1b/2 TEADCO trial of ODM-212 in advanced solid tumours

FDA expands Sanofi and Regeneron's Dupixent approval to younger children with chronic spontaneous urticaria

WuXi Biologics gains MFDS approval for three Wuxi manufacturing sites

OrganaBio and RxMP Therapeutics partner to advance RMP-402 haemostatic drug product

Université Laval and Glycovax Pharma agree exclusive global licence to develop innovative galectin-3 inhibitors

Thryv Therapeutics doses first patients in Wave II clinical study for Long QT Syndrome; THRV-1268 receives FDA Fast Track Designation

WuXi Biologics receives South Korean certification for commercial manufacturing of bispecific antibody therapeutics

PureTech Health reports positive Phase 1b data for LYT-200 in MDS and AML

European Commission approves Ojemda as first targeted therapy for relapsed paediatric low-grade glioma

Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning